Nifty
Sensex
:
:
11456.90
38164.61
-64.15 (-0.56%)
-222.14 (-0.58%)

Pharmaceuticals & Drugs

Rating :
55/99  (View)

BSE: 500087 | NSE: CIPLA

526.80
-6.45 (-1.21%)
22-Mar-2019 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  534.90
  •  539.00
  •  523.60
  •  533.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1579084
  •  8318.61
  •  678.45
  •  483.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 42,448.37
  • 31.70
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 45,580.81
  • 0.57%
  • 2.82

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 36.70%
  • 2.58%
  • 16.33%
  • FII
  • DII
  • Others
  • 0.95%
  • 13.39%
  • 30.05%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.82
  • 8.30
  • 3.69

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.66
  • 2.84
  • -0.21

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.25
  • 0.18
  • 0.99

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.64
  • 37.07
  • 38.23

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.71
  • 3.82
  • 3.47

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.47
  • 18.57
  • 17.98

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
4,007.54
3,913.82
2.39%
4,011.90
4,082.41
-1.73%
3,938.99
3,525.05
11.74%
3,697.97
3,582.00
3.24%
Expenses
3,299.87
3,095.16
6.61%
3,309.68
3,278.02
0.97%
3,212.62
2,878.59
11.60%
3,141.10
3,075.76
2.12%
EBITDA
707.67
818.66
-13.56%
702.22
804.39
-12.70%
726.37
646.46
12.36%
556.87
506.24
10.00%
EBIDTM
17.66%
20.92%
17.50%
19.70%
18.44%
18.34%
15.06%
14.13%
Other Income
78.53
52.93
48.37%
132.57
113.33
16.98%
170.11
151.38
12.37%
40.01
22.79
75.56%
Interest
44.19
9.15
382.95%
44.37
42.02
5.59%
35.09
27.86
25.95%
35.20
33.40
5.39%
Depreciation
293.13
522.35
-43.88%
281.90
302.22
-6.72%
241.00
213.43
12.92%
284.82
632.19
-54.95%
PBT
448.88
340.09
31.99%
508.52
573.48
-11.33%
620.39
556.55
11.47%
199.34
-136.56
-
Tax
125.68
-64.23
-
142.39
137.42
3.62%
173.71
130.77
32.84%
46.15
-75.70
-
PAT
323.20
404.32
-20.06%
366.13
436.06
-16.04%
446.68
425.78
4.91%
153.19
-60.86
-
PATM
8.06%
10.33%
9.13%
10.68%
11.34%
12.08%
4.14%
-1.70%
EPS
4.12
4.98
-17.27%
4.68
5.25
-10.86%
5.60
5.08
10.24%
2.22
-0.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
15,656.40
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
Net Sales Growth
3.66%
5.29%
5.88%
19.83%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
 
Cost Of Goods Sold
5,628.98
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
Gross Profit
10,027.42
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
GP Margin
64.05%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
Total Expenditure
12,963.27
12,702.34
12,369.97
11,115.22
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
Power & Fuel Cost
-
298.82
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
% Of Sales
-
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
Employee Cost
-
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
% Of Sales
-
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
Manufacturing Exp.
-
1,220.67
1,192.77
1,596.79
737.11
644.42
541.58
583.18
627.94
708.39
676.85
% Of Sales
-
8.05%
8.29%
11.75%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
General & Admin Exp.
-
1,002.43
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
% Of Sales
-
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
Selling & Distn. Exp.
-
1,082.90
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
% Of Sales
-
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
Miscellaneous Exp.
-
969.00
1,097.01
83.99
497.67
441.10
355.12
194.07
111.96
185.92
339.15
% Of Sales
-
6.39%
7.62%
0.62%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
EBITDA
2,693.13
2,453.37
2,024.32
2,479.67
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
EBITDA Margin
17.20%
16.19%
14.06%
18.24%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
Other Income
421.22
357.65
228.69
208.21
165.55
265.37
222.14
139.52
91.68
353.50
354.49
Interest
158.85
114.23
159.38
206.63
168.29
145.74
33.91
38.34
25.10
28.30
52.23
Depreciation
1,100.85
949.81
871.46
754.22
504.71
372.64
330.48
312.22
273.33
167.07
151.79
PBT
1,777.13
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
Tax
487.93
250.11
179.76
331.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
Tax Rate
27.46%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
PAT
1,289.20
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
PAT before Minority Interest
1,340.30
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
Minority Interest
51.10
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
PAT Margin
8.23%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
PAT Growth
6.96%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
 
Unadjusted EPS
16.62
17.53
12.52
16.93
14.71
17.29
19.24
14.25
12.32
13.70
9.92

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
Share Capital
161.02
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
Total Reserves
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
Non-Current Liabilities
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
Secured Loans
0.00
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
Unsecured Loans
3,662.11
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
Long Term Provisions
137.92
140.52
144.68
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
Current Liabilities
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
Trade Payables
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
Other Current Liabilities
647.04
908.95
1,006.14
654.55
408.67
250.89
489.93
235.28
192.56
255.44
Short Term Borrowings
435.87
467.23
4,969.67
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
Short Term Provisions
630.19
426.43
324.42
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
Total Liabilities
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
Net Block
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
Gross Block
13,042.25
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
Accumulated Depreciation
2,816.17
1,609.71
799.30
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
Non Current Assets
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
Capital Work in Progress
981.33
1,682.98
2,060.87
580.90
441.84
377.79
371.17
285.34
684.24
366.32
Non Current Investment
157.66
137.36
176.35
249.76
397.14
415.69
328.59
367.18
1.00
1.03
Long Term Loans & Adv.
514.96
543.67
426.18
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
Other Non Current Assets
255.71
210.06
176.54
168.39
151.74
154.88
38.95
30.98
0.00
0.00
Current Assets
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
Current Investments
1,102.21
837.39
582.34
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
Inventories
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
Sundry Debtors
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
Cash & Bank
965.61
638.27
871.40
564.26
175.76
143.01
90.46
95.97
62.06
53.39
Other Current Assets
1,599.13
418.17
437.05
145.60
630.63
468.31
622.17
726.59
2,537.33
1,821.13
Short Term Loans & Adv.
1,122.86
807.84
786.12
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
Net Current Assets
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
Total Assets
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
PBT
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
Adjustment
1,298.59
1,374.42
950.85
630.05
552.80
283.82
396.66
288.84
146.53
252.60
Changes in Working Capital
-783.25
235.44
-429.38
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
Cash after chg. in Working capital
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
Net Fixed Assets
-495.82
-889.04
1,487.25
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
Net Investments
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
Others
-7.10
-391.07
-6,174.87
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
Cash from Financing Activity
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
Net Cash Inflow / Outflow
223.27
-254.13
322.24
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
Opening Cash & Equivalents
610.35
858.15
545.84
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Closing Cash & Equivalent
853.46
610.35
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
175.92
155.15
142.23
133.38
124.79
112.21
95.03
82.91
73.50
55.82
ROA
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
ROE
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
ROCE
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
Fixed Asset Turnover
1.25
1.36
1.40
1.26
1.47
1.69
1.61
1.79
1.94
2.05
Receivable days
68.17
61.60
57.62
57.94
58.66
70.11
77.94
87.29
115.32
118.45
Inventory Days
90.71
91.41
100.43
106.36
93.68
92.19
96.16
97.61
98.17
91.54
Payable days
57.37
48.81
48.67
52.17
44.93
48.58
50.51
56.11
69.48
59.02
Cash Conversion Cycle
101.50
104.20
109.38
112.14
107.41
113.72
123.59
128.78
144.01
150.98
Total Debt/Equity
0.29
0.33
0.46
0.16
0.12
0.11
0.00
0.09
0.00
0.22
Interest Cover
15.61
8.67
9.36
10.83
13.90
62.79
38.76
47.31
47.86
18.15

News Update


  • Cipla's arm completes acquisition of stake in Wellthy Therapeutics
    11th Mar 2019, 09:00 AM

    The company has completed transaction representing an acquisition of 11.71% stake in Wellthy

    Read More
  • Cipla to launch generic Cinacalcet hydrochloride tablets
    6th Mar 2019, 09:13 AM

    Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease

    Read More
  • Cipla wins portion of state ARV tender
    19th Feb 2019, 09:23 AM

    The contract is effective from July 01, 2019 and is valid for three years

    Read More
  • Cipla's arm to acquire 11.71% stake in Wellthy Therapeutics
    19th Feb 2019, 09:02 AM

    The transaction expected to be completed before March 10, 2019

    Read More
  • Cipla's arm completes first stage closing of Avenue Therapeutics
    11th Feb 2019, 11:13 AM

    The transaction representing an acquisition of 33.3% stake in Avenue's capital stock

    Read More
  • Cipla gets final approval from USFDA for Tadalafil Tablets
    7th Feb 2019, 08:57 AM

    According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately $490 million

    Read More
  • Cipla reports 17% fall in Q3 consolidated net profit
    6th Feb 2019, 15:08 PM

    Total income of the company increased by 3.01% at Rs 4086.07 crore for Q3FY19

    Read More
  • Cipla - Quarterly Results
    6th Feb 2019, 14:50 PM

    Read More
  • Cipla receives final approval for generic version of Pfizer’s Depo-Provera
    28th Jan 2019, 09:15 AM

    Medroxyprogesterone Injectable is AB-rated generic therapeutic equivalent version of Pfizer’s Depo-Provera

    Read More
  • Cipla recalling 4,800 bottles of Nevirapine extended release tablets from US
    31st Dec 2018, 10:37 AM

    The main reason for recalling of the bottles is due to failed dissolution specifications

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.